Trial · NCT00839527
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 | Placebo + Metformin + Glimepiride | 0.33 | Standard Error 0.083 | Percentage of HbA1c in the blood | |
| Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 | Pioglitazone + Metformin + Glimepiride | -0.80 | Standard Error 0.055 | Percentage of HbA1c in the blood | |
| Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 | Albiglutide + Metformin + Glimepiride | -0.55 | Standard Error 0.055 | Percentage of HbA1c in the blood | |
| Change From Baseline in HbA1c at Week 104 and Week 156 | Placebo + Metformin + Glimepiride | Week 104, n=12, 130, 104 | -0.32 | Standard Deviation 0.552 | Percentage of HbA1c in the blood |
| Change From Baseline in HbA1c at Week 104 and Week 156 | Pioglitazone + Metformin + Glimepiride | Week 104, n=12, 130, 104 | -1.09 | Standard Deviation 1.119 | Percentage of HbA1c in the blood |
| Change From Baseline in HbA1c at Week 104 and Week 156 | Albiglutide + Metformin + Glimepiride | Week 104, n=12, 130, 104 | -0.76 | Standard Deviation 1.009 | Percentage of HbA1c in the blood |
| Change From Baseline in HbA1c at Week 104 and Week 156 | Placebo + Metformin + Glimepiride | Week 156, n=9, 89, 71 | -0.10 | Standard Deviation 0.923 | Percentage of HbA1c in the blood |
| Change From Baseline in HbA1c at Week 104 and Week 156 | Pioglitazone + Metformin + Glimepiride | Week 156, n=9, 89, 71 | -0.97 | Standard Deviation 1.063 | Percentage of HbA1c in the blood |
| Change From Baseline in HbA1c at Week 104 and Week 156 | Albiglutide + Metformin + Glimepiride | Week 156, n=9, 89, 71 | -0.46 | Standard Deviation 1.113 | Percentage of HbA1c in the blood |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 | Placebo + Metformin + Glimepiride | 0.64 | Standard Error 0.243 | Millimoles per liter (mmol/L) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 | Pioglitazone + Metformin + Glimepiride | -1.74 | Standard Error 0.158 | Millimoles per liter (mmol/L) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 | Albiglutide + Metformin + Glimepiride | -0.69 | Standard Error 0.159 | Millimoles per liter (mmol/L) | |
| Change From Baseline in FPG at Week 104 and Week 156 | Placebo + Metformin + Glimepiride | Week 104, n=12, 128, 103 | 0.43 | Standard Deviation 3.346 | Millimoles per liter (mmol/L) |
| Change From Baseline in FPG at Week 104 and Week 156 | Pioglitazone + Metformin + Glimepiride | Week 104, n=12, 128, 103 | -1.98 | Standard Deviation 3.471 | Millimoles per liter (mmol/L) |
| Change From Baseline in FPG at Week 104 and Week 156 | Albiglutide + Metformin + Glimepiride | Week 104, n=12, 128, 103 | -0.99 | Standard Deviation 3.083 | Millimoles per liter (mmol/L) |
| Change From Baseline in FPG at Week 104 and Week 156 | Placebo + Metformin + Glimepiride | Week 156, n=9, 88, 71 | -0.50 | Standard Deviation 4.093 | Millimoles per liter (mmol/L) |
| Change From Baseline in FPG at Week 104 and Week 156 | Pioglitazone + Metformin + Glimepiride | Week 156, n=9, 88, 71 | -1.94 | Standard Deviation 3.127 | Millimoles per liter (mmol/L) |
| Change From Baseline in FPG at Week 104 and Week 156 | Albiglutide + Metformin + Glimepiride | Week 156, n=9, 88, 71 | -0.88 | Standard Deviation 2.652 | Millimoles per liter (mmol/L) |
| Time to Hyperglycemia Rescue | Placebo + Metformin + Glimepiride | 49.57 | 95% Confidence Interval 38.86 to 55.14 | Weeks | |
| Time to Hyperglycemia Rescue | Pioglitazone + Metformin + Glimepiride | NA | 95% Confidence Interval NA to NA | Weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00839527/results